An Eight- Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Proof of Concept Study to Assess the Efficacy, Safety and Tolerability as well as the Pharmacokinetic Profile of oral Solabegron (GW427353) 125mg and 50mg Administered Twice Daily vs Placebo in Women with Overactive Bladder The primary objective of this study is to compare the efficacy of solabegron 125mg and 50mg administered twice daily, to that of placebo in female subjects with OAB including symptoms of urgency with ...

• Country None
• organs None
• Specialty None

Randomized, Open Label, Active Controlled (Mometasone Furoate Aqueous Nasal Spray [Nasonex®] 200mcg QD), Parallel Group, Multi-Centre, 52-Week Study to Assess the Long Term Safety of GW685698X Aqueous Nasal Spray 100mcg QD via nasal Biopsy in Subjects ≥18 Years of Age with Perennial Allergic Rhinitis (PAR) The primary objective of this study is to determine effects to the nasal mucosa of PAR subjects after one year of continuous treatment with GW685698X aqueous nasal spray 100mcg QD compared to a mometa...

• Country None
• organs None
• Specialty None

A randomized, double-blind, placebo controlled, parallel group, multi-centre, 2-week treatment study to evaluate the safety and efficacy of fluticasone furoate nasal spray (FFNS) 110 mcg, administered either once daily or twice daily, compared with placebo, as effective monotherapy in the treatment of uncomplicated acute rhinosinusitis (ARS) in adult and adolescent subjects 12 years of age and older The objective of this study is to evaluate the safety and efficacy of two doses of FFNS (110 mcg once daily and 110 mcg twice daily) compared to placebo as monotherapy in the treatment of adult and ad...

• Country None
• organs None
• Specialty None

A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with COPD The primary objective of this study is to evaluate the dose response, dose interval, efficacy, and safety of GSK961081 by studying three QD doses (100mcg, 400mcg and 800mcg) and three BID doses (100mc...

• Country None
• organs None
• Specialty None

A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD) To evaluate safety and efficacy of FF/GW642444 50mcg/25mcg QD and FF/GW642444 100mcg/25mcg QD and FF/GW642444 200mcg/25mcg QD versus GW642444 25mcg QD on the annual rate of moderate and severe exacerb...

• Country None
• organs None
• Specialty None

A multicenter trial comparing the efficacy and safety of GSK573719/GW642444 with GSK573719 with tiotropium over 24 weeks in subjects with COPD The primary objective is to compare the efficacy of two doses of GSK573719/GW642444 Inhalation Powder (125mcg/25mcg and 62.5/25mcg once-daily) with GSK573719 (125mcg once daily) and with tiotropium (1...

• Country None
• organs None
• Specialty None

Clinical Evaluation of lamotrigine in Epilepsy To provide confidence in the safety of LTG, as measured by the incidence of rash (including SJS and any other serious drug eruption) in the first 8 weeks of treatment, in Japanese patients with epilep...

• Country None
• organs None
• Specialty None

Study evaluating safety and efficacy of mepolizumab in the treatment of COPD patients with frequent exacerbations To evaluate the efficacy and safety of mepolizumab 100 mg subcutaneous (SC) given every 4 weeks compared to placebo on the frequency of moderate and severe exacerbations in COPD subjects at high risk...

• Country None
• organs None
• Specialty None

PM1116197 is a Clinical Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo 1. Losmapimod kezelés a p38 kináz, mint terápiás célpont gátlására és az akut koronária-betegséget követő kimenetel módosítására (LATITUDE)-TIMI 60 2. Egy új készítmény vizsgálata szívrohamon átesett betegek kezelésére The primary objective is to evaluate the efficacy of oral losmapimod 7.5 mg BID compared to placebo when added to standard of care in subjects with ACS on the time to first occurrence of adjudicated M...

• Country None
• organs None
• Specialty None

A six week randomized, double-blind, multi-center, placebocontrolled, exploratory, adaptive design study to explore the antidepressant properties of the p38 MAP kinase inhibitor GW856553 compared to placebo in adult subjects with Major Depressive Disorder To evaluate the clinical antidepressant effects of GW856553 versus placebo treatment at Week 6 in adult subjects diagnosed with MDD with symptoms of decreased energy and interest, and with psychomotor...

• Country None
• organs None
• Specialty None